By Anthony Silva, WBZ NewsRadio 1030

LEXINGTON (CBS) – A Lexington biotechnology company that’s been struggling to gain market share is buying a smaller competitor.

AMAG Pharmaceuticals is merging with Allos Therapeutics of Colorado in an all stock deal worth $686 million.

WBZ NewsRadio 1030’s Anthony Silva reports

While AMAG is developing a therapeutic iron compound to treat anemia, Allos is developing anti-cancer therapeutics.

Allos will eventually close its operations in Colorado, and move the company to AMAG’s Massachusetts location.

The combined company will also have a new name,  which is still under development.


Leave a Reply

Please log in using one of these methods to post your comment:

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

More From CBS Boston

Opioid Crisis
Download Our App